GlassScriptPhysician profile
Brittany Kolanski
NPI 1851740260
$3,579.40
in general payments reported to CMS, 2019-2025
19 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $640 · 2023: $692 · 2024: $1,010 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,601.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,145.28 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $450.14 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $397.99 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Supernus Pharmaceuticals, INC. | $396.01 | 2023-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $174.80 | 2022-2025 | Uzedy, Austedo Xr |
| Alkermes, INC. | $149.85 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $142.06 | 2021-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $136.38 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $109.80 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $102.26 | 2025 | Invega, Spravato |
| E.R. Squibb & Sons, L.L.C. | $83.84 | 2024-2025 | Cobenfy |
| Corium, LLC | $57.60 | 2022-2023 | Azstarys |
| Collegium Pharmaceutical, INC. | $55.95 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $52.30 | 2023-2025 | Trintellix |
| Janssen Scientific Affairs, LLC | $39.24 | 2025 | Spravato |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $28.04 | 2023 | Auvelity |
| Indivior INC. | $27.92 | 2023 | Perseris |
| Tris Pharma INC | $15.04 | 2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $14.90 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Kolanski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.